Literature DB >> 6432804

The natural heterogeneity of Trypanosoma cruzi: biological and medical implications.

J A Dvorak.   

Abstract

Trypanosoma cruzi is a heterogeneous group of parasites. The imposition of natural or artificial pressures can result in the selection of subsets of the population with concomitant changes in characteristics used to evaluate the group. In order to ascertain the extent of heterogeneity, stocks of single-cell clones were prepared from various sources. Selected cell biological, biochemical, immunochemical, parasitological, and histopathological parameters of these clones have been studied. A ten-fold difference in the rate of growth of the epimastigote stage of T cruzi clones has been observed. The extracellular growth rates of the clones correlate with the rate of growth of the obligate intracellular amastigote stage and consequently, the length of intracellular cycle of the parasite. A 40% difference in the amount of total DNA/parasite has been found between clones. Although the amount of DNA/kinetoplast and nucleus varies between clones, the major contribution to the differences in total DNA/parasite appears to be the nucleus. From 16 to 35 antigens have been demonstrated in the T cruzi clones assayed to date. Five to seven of these antigens are common to all of the stocks assayed. However, both isolate- and clone-specific antigens have also been demonstrated. The susceptibility of inbred strains of mice to T cruzi clones varies with the clone of the parasite. These data imply that the genetics of the parasite as well as the host modulate both the course and outcome of a T cruzi infection. The influence of monosaccharides on the receptor-mediated infection of vertebrate cells by trypomastigotes of T cruzi also varies between clones. The implications of these findings upon our concept and understanding of present and future problems in Chagas disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432804     DOI: 10.1002/jcb.240240406

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  26 in total

1.  Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.

Authors:  Denise da Gama Jaén Batista; Marcos Meuser Batista; Gabriel Melo de Oliveira; Patrícia Borges do Amaral; Joseli Lannes-Vieira; Constança Carvalho Britto; Angela Junqueira; Marli Maria Lima; Alvaro José Romanha; Policarpo Ademar Sales Junior; Chad E Stephens; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  The Hsp70/J-protein machinery of the African trypanosome, Trypanosoma brucei.

Authors:  Stephen John Bentley; Miebaka Jamabo; Aileen Boshoff
Journal:  Cell Stress Chaperones       Date:  2018-12-01       Impact factor: 3.667

3.  Two approaches to discovering and developing new drugs for Chagas disease.

Authors:  J H McKerrow; P S Doyle; J C Engel; L M Podust; S A Robertson; R Ferreira; T Saxton; M Arkin; I D Kerr; L S Brinen; C S Craik
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

Review 4.  Pathogenesis of chagas' disease: parasite persistence and autoimmunity.

Authors:  Antonio R L Teixeira; Mariana M Hecht; Maria C Guimaro; Alessandro O Sousa; Nadjar Nitz
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

5.  Variation in antigenic determinants specific to the infective stage of Trypanosoma cruzi.

Authors:  R A Wrightsman; W Leon; J E Manning
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

6.  Two hybridization events define the population structure of Trypanosoma cruzi.

Authors:  Scott J Westenberger; Christian Barnabé; David A Campbell; Nancy R Sturm
Journal:  Genetics       Date:  2005-07-05       Impact factor: 4.562

7.  Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.

Authors:  Juan C Engel; Kenny K H Ang; Steven Chen; Michelle R Arkin; James H McKerrow; Patricia S Doyle
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

8.  Selective binding of Trypanosoma cruzi to host cell membrane polypeptides.

Authors:  C D Davis; R E Kuhn
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

9.  Natural populations of Trypanosoma cruzi, the agent of Chagas disease, have a complex multiclonal structure.

Authors:  M Tibayrenc; P Ward; A Moya; F J Ayala
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

10.  Flow cytometric analysis of the DNA synthetic cycle of Candida species.

Authors:  J A Dvorak; W L Whelan; J P McDaniel; C C Gibson; K J Kwon-Chung
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.